Drug Trial Radar · NCT02008123
Effect of Primidone on Platelet Responsiveness in Patients Determined to be Clopidogrel Resistant
Last checked: Nov 19, 2026Latest source record: Aug 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Aug 2013
Primary completion
Dec 2017
Sponsor
- Lead sponsor
- Dent Neuroscience Research CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 11, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether adding primidone will improve the metabolism of clopidogrel thereby increasing metabolite levels within the blood stream and platelet response to clopidogrel in patients who were previously found to lack adequate response to clopidogrel. This information could help overcome clopidogrel resistance in patients who are at risk for stroke or transient ischemic attack (TIA).
Conditions
- Clopidogrel Resistance
- Secondary Stroke Prevention
Interventions
PrimidoneDrug
Primidone is an antiepileptic used for the management of generalized tonic-clonic seizures and for the management of complex partial seizures. One of primidone's active metabolite is phenobarbital, which is a potent cytochrome P450 inducer. In this study, primidone will be used to induce CYP 1A2 in order to provide more efficient metabolism of clopidogrel to its active form
Primary outcomes
What the sponsor says the trial is designed to measure.
- Platelet AggregometryTime frame: Platelet aggregometry will be performed at Visit 1 and Visit 2 which will be 20-28 days following Visit 1.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dent Neurologic Institute
Amherst, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.